

Search Results Project Details

[Share](#)
[Back to Search Results](#)

Epidemiology and Genetics of Susceptibility to COVID-19 Infection

- [Description](#)
- [Details](#)
- [Sub-Projects](#)
- [Publications](#)
- [Patents](#)
- [Outcomes](#)
- [Clinical Studies](#)
- [News and More](#)
- [History](#)
- [Similar Projects](#)

Project Number
1ZIACP101233-01

Contact PI/Project Leader
SAVAGE, SHARON A.

Awardee Organization
DIVISION OF CANCER
EPIDEMIOLOGY AND
GENETICS

Description

Abstract Text

Infection by the acute respiratory syndrome coronavirus 2 (SARS-CoV-2) results in the infectious disease syndrome known as coronavirus disease 2019 (**COVID-19**). SARS-CoV-2 was originally described in late 2019 in Wuhan, China and has since spread throughout the world causing the 2019-2020 **COVID-19** pandemic. While many individuals with SARS-CoV-2 infection may have mild or few symptoms, others have life threatening illness including severe pneumonia and multi-organ failure. As of May 12, 2020, there have been 1,342,594 cases and 80,820 deaths in the United States due to **COVID-19** (<https://cdc.gov>). This approximately 6% death rate and lack of effective treatment or prevention measures illustrates the urgent need to understand factors associated with risk of severe **COVID-19** disease. Irrespective of the actual rate of severe disease and death, it is clear that there will be enormous numbers of severe cases worldwide and management strategies are desperately needed. This is a multi-disciplinary collaborative project with the primary aim of understanding why some individuals with **COVID-19** infection have mild clinical symptoms, while others have very severe disease resulting in respiratory failure, multi-organ failure, and death. The multiple aims of this project utilize the wide-ranging expertise of scientists in the Division of Cancer Epidemiology and Genetics, NCI1) Identify common and rare germline genetic variants associated with risk of **COVID-19** infection and outcomes; 2) Identify other biomarkers associated with risk of **COVID-19** infection and outcomes; 3) Characterize the contribution of co-morbid conditions, including current or prior cancer to **COVID-19** infection and outcomes; 4) Conduct descriptive epidemiology studies aimed at understanding the population-level consequences of **COVID-19** on public health and disease; 5) Identify optimal testing strategies to detect and monitor **COVID-19** in populations; and 6) Deposit and share data as fast as possible

Public Health Relevance Statement

Data not available.

NIH Spending Category

Cancer Clinical Research Coronaviruses Emerging Infectious Diseases
Genetics Infectious Diseases Lung Prevention

Project Terms


2019-nCoV Acute Acute respiratory infection Authorization documentation
Biological Markers COVID-19 COVID-19 pandemic Cessation of life China
Clinical Communicable Diseases Communities Coronavirus Data

Thank you for your feedback!

Death Rate Deposition Descriptive Epidemiology Disease
 Division of Cancer Epidemiology and Genetics Epidemiology Failure
 Genetic Predisposition to Disease Individual Infection Life
 Malignant Neoplasms Monitor Outcome Pneumonia Population
 Prevention Measures Public Health Research Personnel Respiratory Failure

 **Details**

Contact PI/ Project Leader

Name
[SAVAGE, SHARON A.](#) 
 Title
BRANCH CHIEF
 Contact
savagesh@mail.nih.gov

Other PIs

Not Applicable

Program Official

Name
 Contact
Email not available Email not available

Organization

Name
DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS
 City
 Country
 Department Type
Unavailable
 Organization Type
Unavailable
 State Code
 Congressional District

Other Information

FOA
 Study Section
 Fiscal Year
2020
 Award Notice Date
 Administering Institutes or Centers
NATIONAL CANCER INSTITUTE
 DUNS Number CFDA Code
 Project Start Date
 Project End Date
 Budget Start Date
 Budget End Date

Project Funding Information for 2020

Total Funding
\$867,010
 Direct Costs
\$0
 Indirect Costs
\$0

Year	Funding IC	FY Total Cost by
2020	NATIONAL CANCER INSTITUTE	\$867,010

NIH Categorical Spending

[Click here for more information on NIH Categorical Spending](#)

Funding IC	FY Total Cost by IC	NIH Spending Category
DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS	\$867,010	Cancer; Clinical Research; Coronaviruses; Emerging Infectious Diseases; Genetics; Infectious Diseases; Lung; Prevention;

Thank you for your feedback!

 **Sub Projects**

No Sub Projects information available for 1ZIACP101233-01

 **Publications**

No Publications available for 1ZIACP101233-01

 **Patents**

No Patents information available for 1ZIACP101233-01

 **Outcomes**

The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.

No Outcomes available for 1ZIACP101233-01

 **Clinical Studies**

No Clinical Studies information available for 1ZIACP101233-01

 **News and More****Related News Releases**

No news release information available for 1ZIACP101233-01

 **History**

No Historical information available for 1ZIACP101233-01

 **Similar Projects**

No Similar Projects information available for 1ZIACP101233-01

Thank you for your feedback!